Mylan launches Hepatitis C drug Harvoni in India
Advertisement
New Delhi: Drug firm Mylan NV has launched generic Harvoni tablets, used to treat Hepatitis C, under the brand name 'MyHep LVIR' in India.
Mylan Pharmaceuticals Pvt Ltd, a subsidiary of the company has launched generic Harvoni in the country, Mylan NV said in a statement.
"Mylan recognises the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus," Mylan President Rajiv Malik said.
MyHep LVIRTM is an important addition to the company's growing Hepato Care segment in India that gives it an opportunity to offer patients the potential to be cured through a transformative and simplified single tablet, once- daily treatment regimen, he added.
The launch of MyHep LVIRTM follows the launch of generic Sofosbuvir in India under the brand name MyHepTM in April, 2015.
In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead that granted the former non-exclusive rights to manufacture and distribute generic Sofosbuvir and Ledipasvir/Sofosbuvir tablets in 101 developing countries, including India.
Mylan also entered into an agreement with Gilead in February 2015, as the exclusive distributor of Gilead's branded Sovaldi (Sofosbuvir 400 mg) and Harvoni tablets in India.
Mylan launched Sovaldi in India in May 2015.
There are around 12 million people who are chronically infected with Hepatitis C in India. MyHep LVIRTM is a single-tablet regimen and requires a therapy course of just 12 weeks.
Mylan Pharmaceuticals Pvt Ltd, a subsidiary of the company has launched generic Harvoni in the country, Mylan NV said in a statement.
"Mylan recognises the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus," Mylan President Rajiv Malik said.
MyHep LVIRTM is an important addition to the company's growing Hepato Care segment in India that gives it an opportunity to offer patients the potential to be cured through a transformative and simplified single tablet, once- daily treatment regimen, he added.
The launch of MyHep LVIRTM follows the launch of generic Sofosbuvir in India under the brand name MyHepTM in April, 2015.
In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead that granted the former non-exclusive rights to manufacture and distribute generic Sofosbuvir and Ledipasvir/Sofosbuvir tablets in 101 developing countries, including India.
Mylan also entered into an agreement with Gilead in February 2015, as the exclusive distributor of Gilead's branded Sovaldi (Sofosbuvir 400 mg) and Harvoni tablets in India.
Mylan launched Sovaldi in India in May 2015.
There are around 12 million people who are chronically infected with Hepatitis C in India. MyHep LVIRTM is a single-tablet regimen and requires a therapy course of just 12 weeks.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.